Although SPARC has been reported to be dysregulated in several different types of cancers48,49, has been associated with prostate cancer progression and bone metastasis50–53, and has been suggested as a possible target for cancer therapeutics48,54,55, the elevated global protein level of SPARC in this study was determined to be nonspecific for prostate cancer. The gene discussed is SPARC; the disease is Familial prostate cancer.